Shared on16 Aug 25Fair value Decreased 11%
The consensus Analyst Price Target for STRATA Skin Sciences has been revised downward, primarily reflecting a notable decline in the Future P/E multiple, resulting in a reduction of fair value from $9.00 to $8.00. What's in the News STRATA Skin Sciences is collaborating with CMS to secure temporary reimbursement codes for its XTRAC excimer laser treatment, aiming to accelerate access to newly expanded reimbursement indications as early as the 2026 rule cycle.
Shared on24 Apr 25Fair value Decreased 21%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.